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Abstract
Background: According to international guidelines, treatment of inflammatory arthritis should be based on a
shared decision between patient and rheumatologist. Furthermore, patients with inflammatory arthritis have high
need of information and want to be more actively involved in medical decision-making. To facilitate shared
decision-making and support patients in choosing between disease modifying anti-rheumatic drugs (DMARDs), a
web-based patient decision aid (PtDA) was developed. This study evaluated use, appreciation and effect of this
PtDA.
Methods: A post-test only study with a historical comparison group was conducted. In a two-year period, all
patients diagnosed with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis, who were deciding
whether to start a (different) DMARD were invited to participate. In the first year, patients received standard
information (comparison group). In the second year, patients were referred to the PtDA (intervention group). In
both groups, a questionnaire was sent four weeks after consulting the rheumatologist. Patient characteristics
included sociodemographic, health-related and preference-related variables. Process measures were for use and
appraisal of the PtDA (intervention group only). The primary outcome measure was patients’ perceived role in
medical decision-making. Secondary outcome measures comprised satisfaction with the decision-making process
and the decision, beliefs about medication, adherence to medication and trust in the physician.
Results: We received 158/232 questionnaires (68 %) from the comparison group and 123/200 (61 %) from the
intervention group. The PtDA was used by 69/123 patients (57 %) in the intervention group. Patients who used the
PtDA highly appreciated it and perceived it as easy to use and helpful. Relative to the comparison group, patients
in the intervention group perceived a more active role in medical decision-making and decisions were more in line
with patients’ personal preferences. Other outcomes showed no significant difference between the two groups.
Conclusion: The web-based PtDA was highly appreciated and perceived as helpful for decision-making.
Implementation of the PtDA in rheumatology practice was associated with a significantly larger proportion of
patients perceiving an active role in medical decision-making and decisions were more in line with patients’
personal preferences. The PtDA can be a valuable aid in improving patient participation in decision-making about
DMARDs.
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Background
In recent years, several studies have shown that patients
with inflammatory arthritis have a high need of informa-
tion and want to be more actively involved in medical
decision-making [1–8]. Medical decisions in this popula-
tion focus primarily on the management of the disease
with conventional synthetic disease modifying anti-
rheumatic drugs (csDMARDs) and biologic disease
modifying anti-rheumatic drugs (bDMARDs). When
weighing the options, elements to consider include treat-
ment efficacy, approximate time to benefit, possible side
effects, current and future risks, cost-effectiveness, route
of administration and impact on daily life. Given the
preference-sensitive elements of these treatment options,
treatment of inflammatory arthritis should be based on a
shared decision between the patient and the rheuma-
tologist [9–12].
While desirable, implementing shared decision-making
(SDM) in daily clinical practice is challenging. Patients
often find it hard to recognise that a decision needs to be
made and find it difficult to actively participate in the
process to come to an informed values-based decision [8,
13]. Physicians, on the other hand, may be uncomfortable
with patient involvement due to a lack of time, self-efficacy
or skills [14].
To facilitate SDM and to support patients in making
treatment decisions, patient decision aids (PtDAs) have
been developed for a wide variety of conditions and treat-
ments [15]. PtDAs make the decision being considered ex-
plicit, describe all available treatment options and their pros
and cons, and help patients to consider the options from a
personal perspective [16, 17].
PtDAs have repeatedly been shown to have a positive
impact on patients’ knowledge about options, accurate
risk perceptions and feelings of being informed [15].
Moreover, PtDAs have improved patients’ involvement
in medical decision-making and have led to decisions
that are more in line with patients’ personal preferences
[15]. Furthermore, PtDAs sometimes have a positive im-
pact on patients’ satisfaction with decision-making, anx-
iety, adherence or health outcomes [15]. Although these
effects are not likely to be very different, in rheumatol-
ogy, only a few studies on PtDAs have been reported
and their effects have not yet been thoroughly deter-
mined [18–20].
With the objective of supporting SDM in rheumatol-
ogy, we developed a web-based PtDA for initiating
csDMARDs and bDMARDs. We have previously de-
scribed the systematic development of this PtDA [21]
using the development process model of the Inter-
national Patient Decision Aids Standards (IPDAS) [22]
combined with user-centred design methods [23, 24].
We conducted a study to evaluate the use, appreci-
ation and effect of the PtDA. The study focused on
answering the following research questions: (1) how
many patients use the PtDA; (2) what are determi-
nants of use; (3) how do patients appreciate the
PtDA; and (4) in comparison to usual care, what is the ef-
fect of the PtDA on patients’ perceived role in medical
decision-making, satisfaction with the decision and
decision-making process, beliefs about medication, adher-
ence and trust in the physician? The primary outcome of
the study was the impact of the PtDA on patients’ per-
ceived role in medical decision-making, in comparison to
usual care. We also examined use of the PtDA by patients,
determinants of use and patients’ appreciation of the
PtDA. Furthermore, we explored the impact on satisfac-
tion with the decision and the decision-making process,
beliefs about medication, adherence to medication, and
trust in the physician.
Methods
Description of the PtDA and its integration in clinical
practice
The PtDA is intended for patients diagnosed with
rheumatoid arthritis (RA), ankylosing spondylitis (AS)
or psoriatic arthritis (PsA), who face the decision
whether to initiate a DMARD or change to a different
DMARD. Based on previous work [25, 26], the tool
was designed to enable patients to compare multiple
DMARDs with regard to both clinical and practical
information with possible consequences for daily life.
Furthermore, it aims to support patients in determin-
ing treatment preferences, worries and questions and
to help patients to express these feelings and ques-
tions to the health professionals.
Ideally, the PtDA is integrated into the patient path-
way, as illustrated in Fig. 1. First, the rheumatologist
and patient have an initial conversation about starting
a (different) DMARD. During this conversation the
rheumatologist refers the patient to the web-based
PtDA with use of a card. On this referral card the
rheumatologist ticks the DMARDs appropriate for
this individual patient. The referral card also states
the Internet address of the PtDA. After the conversa-
tion, the patient can use the PtDA at home. The
web-based PtDA consists of various parts: (1) general
information about shared decision-making, inflamma-
tory arthritis (RA, AS and PsA) and DMARDs; (2) an
application to compare the particular DMARDs ticked
on the card by the rheumatologist; (3) exercises to
gain insight into preferences, worries and questions;
and (4) a printed summary with the patients’ notes,
preferences, worries and questions to be discussed
with the rheumatologist at the next consultation. The
PtDA is in Dutch, but can be visited via
www.reumamedicatiekeuzehulp.nl.
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Study design
A post-test only study with non-equivalent groups was
conducted. In this design two nonrandomized groups
are compared in a post-test design. In this study, a his-
torical comparison group was used, i.e. the comparison
group preceded the intervention group in time.
The study covered a two-year period. In the first year,
patients received standard information (comparison
group). This standard information consisted of a one
page information leaflet briefly describing the DMARD
under consideration. It described the intended effect,
possible interactions with other medicines, the manner
of administration, the follow-up process, a short list with
common and important side effects, and possible impact
on fertility, pregnancy and breastfeeding. In the second
year, patients were referred to the PtDA (intervention
group), as described earlier. A questionnaire was sent
four weeks after inclusion.
Patients and procedure
Patients were recruited from two large teaching hospitals
in the Netherlands: Medisch Spectrum Twente and
Ziekenhuisgroep Twente. Both participating hospitals
work according to shared standard operating procedures
on how to provide treatment information, which are in
line with national guidelines. This practice is uniform
across the six rheumatologists in each hospital.
All consecutive patients diagnosed with RA, PsA or
AS who visited one of the clinics and discussed initiating
a (different) DMARD were informed about the study by
their rheumatologist (the same rheumatologists in both
years of the study) and asked to give permission for the
researcher to contact them. Patients who participated in
the comparison group were excluded from participation
in the intervention group by the researcher (IN).
Patients who agreed to participate (232 patients in the
first year; 200 patients in the second year) were sent the
questionnaire by mail, four weeks after the consultation.
The questionnaire was accompanied by a letter from
their rheumatologist and an informed consent form. The
letter stated the decision and the treatment options as
discussed at the time of inclusion. Patients were asked to
return the completed questionnaires and informed con-
sent form to the university using a prepaid return enve-
lope. After three weeks a reminder was sent to those
who had not yet returned the questionnaire.
Measurements
The questionnaire contained questions on patient char-
acteristics, process measures and outcome measures.
Our calculated measurements and the statistics for in-
ternal consistency are subsequently described for each
measure. Standardized scales were used as much as pos-
sible. If there was no Dutch scale available, scales were
translated using the forward-backward procedure [27].
Patient characteristics
Patient characteristics included sociodemographic, health-
related and preference-related variables and treatment op-
tions as suggested by the rheumatologist. Sociodemo-
graphics included gender, age, marital status, education
level and work status.
Health-related variables included diagnosis, time since
diagnosis, pain and physical function. Pain was assessed
as arthritis-related pain in the prior week with a 0 to 10
numerical rating scale. To measure physical function we
used the 10-item Health Assessment Questionnaire
version 2 (HAQ-II) [28]. Mean scores range from 0
(minimal loss of function) to 3 (completely disabled)
(Cronbach’s α = 0.92).
Preference-related variables included role preference
in decision-making about DMARDs and need for infor-
mation. Role preference was assessed using the Control
Preferences Scale (CPS) [29] adapted by Garfield et al.
[5]. Patients were asked: “If you are informed about the
benefits and risks, who should finally decide about initi-
ating DMARDs?” and could respond on a 5-point scale:
1 (the rheumatologist), 2 (mostly the rheumatologist), 3
Fig. 1 Process of the patient decision aid (PtDA) [21]
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(the rheumatologist and me together), 4 (mostly me),
and 5 (me alone). The answers were summarized into
the values 1 ((mostly) doctor), 2 (shared) and 3 ((mostly)
patient), as validated by Degner et al. [29]. Need for
information was measured with a 4-item subscale for
“need for clarification of medical facts” from the Co-
logne Patient Questionnaire (CPQ) [30, 31]. Mean scores
range from 1 to 5 with a higher score indicating higher
need for information (Cronbach’s α = 0.83).
Process measures
Process measures evaluated the use and appraisal of the
PtDA (intervention group only). Use of the PtDA was
assessed by asking respondents if they had (1) received
the referral card, (2) received an explanation about the
PtDA and (3) had visited the PtDA website. Reasons for
not visiting the PtDA website were also assessed. Users
of the PtDA were asked which tasks they performed on
the PtDA website. Response options are specified in
Table 2.
Appraisal of the PtDA was assessed with constructs
including subjective impact of the PtDA (five items;
Cronbach’s α = 0.84), perceived usefulness (eight items;
Cronbach’s α = 0.88), ease of use (four items; Cronbach’s
α = 0.87), attractiveness (two items; Cronbach’s α = 0.97),
and attitude towards future use (two items; Cronbach’s
α = 0.92). The latter four constructs are based on the
Technology Acceptance Model (TAM) [32, 33]. State-
ments related to general and specific elements of the
PtDA. Items and response options are specified in
Table 4. Mean construct scores range from 1 to 5 with
higher scores reflecting higher appraisal. Finally, respon-
dents were asked to rate the overall quality of the PtDA
in a range from 0 to 10.
Outcome measures
Our primary outcome measure was patients’ perceived
role in medical decision-making. Secondary outcome
measures comprised satisfaction with the decision and
decision-making process. Other secondary outcome mea-
sures comprised beliefs about medication, adherence and
trust in the physician. All outcome measures specifically
focused on the decision that patients discussed with their
rheumatologist at the time of inclusion. Rheumatologists
registered which treatment options they suggested.
Perceived role in medical decision-making was
assessed with the CPS [5, 29]. This measure was also
used to assess patients’ preferred role. To assess per-
ceived role, patients were asked: “In your opinion, who
finally made this decision?” Patients could respond on a
5-point scale (see previous text). Scores were summa-
rized into the values 1 ((mostly) doctor), 2 (shared) and
3 ((mostly) patient).
Satisfaction with the decision and decision-making
process was assessed with 6 scales: satisfaction with
participation, satisfaction with amount of received infor-
mation, informed choice, decision control, satisfaction-
uncertainty and consistency with personal values. The
scale for satisfaction with participation was developed
for this study by the researchers and also consists of five
items: “My rheumatologist asked me my opinion on this
decision”; “I expressed my opinion on this decision”;
“There was enough time for questions”; “I was able to
express my questions, worries and doubts” and “My
questions were answered”. Mean scale scores range from
1 to 5 with a higher score indicating higher levels of sat-
isfaction with participation (Cronbach’s α = 0.71).
Satisfaction with the amount of information received
was assessed with items based on the Satisfaction with
Information about Medicines Scale (SIMS) [34]. Respon-
dents rated the amount of information received. It ori-
ginally includes seventeen items (i.e. information topics),
we added four items based on the Dutch legal standards
for informed consent: the dosage, frequency of adminis-
tration, storage and storage life. Response options are: 0
(no, far too little), 1 (no, little too little) and 2 (yes,
sufficient), which were recoded into 0 (no) and 1
(yes). The sum scores range from 0 to 21 with higher
scores indicating a higher degree of overall satisfac-
tion with the amount of information received (Cronbach’s
α = 0.91).
The Dutch Decision Evaluation Scales (DES) [35] were
used to assess (1) informed choice: the patient’s percep-
tion of the quality of the received information (5 items
α = 0.86); (2) decision control: the patient’s perceived
level of control over the decision in terms of feelings of
regret, anxiety and deciding under pressure (5 items,
α = 0.62); and (3) satisfaction-uncertainty: the extent
to which a patient is satisfied or still has doubts
about the decision (5 items, α = 0.56). Scale scores
range from 1 to 5 with higher scores indicating
higher levels of informed choice, decision control and
higher satisfaction (less uncertainty).
The consistency with personal values scale is a two-
item subscale of the Satisfaction With Decision (SWD)
scale [36] and measures whether the decision meets per-
sonal preferences (Cronbach’s α = 0.79). Mean scale
scores for both scales range from 1 to 5 with a higher
score indicating higher consistency.
Other secondary outcome measures comprised pa-
tients’ beliefs about DMARDs, adherence and trust in
the physician. Patients’ beliefs about DMARDs were
assessed with the Beliefs about Medicines Questionnaire
(BMQ) [37]. The BMQ includes two 5-item subscales
assessing patients’ beliefs about the necessity of medica-
tion and their concerns about it. Sum scores for both
scales range from 5 to 25 with higher scores indicating
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stronger beliefs (Cronbach’s α = 0.83 and α = 0.73,
respectively).
Adherence was measured in participants who self-
administered their DMARDs. Participants who had help
from a caregiver or who went to the clinic for adminis-
tration (e.g. intravenous therapy) were excluded from
the analysis. We used the 8-item Morisky Medication
Adherence (MMA) scale [38]. Sum scores range from 0
to 8 with higher scores representing more adherent be-
haviour (Cronbach’s α = 0.77).
Trust in the physician was assessed with a 3-item
subscale of the Cologne Patient Questionnaire (CPQ)
[30, 31]. Mean scale scores range from 1 to 5 with a
higher score indicating greater trust (Cronbach’s α = 0.90).
Treatment options suggested by the rheumatologist
were registered at the time of inclusion by the rheuma-
tologist after obtaining the patient’s consent. We
counted the number of suggested options and grouped it
into “one option” or “more than one option”. If combin-
ation therapy was suggested (e.g. methotrexate combined
with hydroxychloroquine or methotrexate combined with
adalimumab) and no alternative options were presented, it
was coded as one option.
Pilot test
Prior to inclusion, we performed a pilot test among pa-
tients (n = 10) to assess the readability of the question-
naire and acceptability of the time it takes to complete
the questionnaire. The test showed that the questionnaire
took about 30 minutes to complete, which was acceptable
according to the participants. Minor textual adjustments
were made following the results of the pilot test.
Statistical analysis
The Statistical Package for the Social Sciences (version
21.0 IBM SPSS Inc, Chicago, IL, USA) [39] was used to
perform all analyses. The Pearson chi-square test (for
categorical variables) and t test (for continuous vari-
ables) were performed to compare characteristics of the
comparison group and the intervention group, to exam-
ine which factors were associated with use of the PtDA
and to evaluate the impact of the PtDA.
Results
Patient characteristics
The patients in the comparison group returned 158/232
questionnaires (response rate 68 %), from the intervention
group we received 123/200 (response rate 61 %). Within
both the comparison group and the intervention group
there were no significant differences between respondents
and non-respondents in age, gender, diagnosis and amount
of options suggested by the rheumatologist.
The comparison group and intervention group did not
differ with regard to sociodemographic, health-related or
preference-related variables, except for marital status
(Table 1). In both groups mean age was about 55 years,
most respondents were women and most were diagnosed
with RA. Both groups reported having a high need for med-
ical information and most participants preferred shared
decision-making.
Use of the PtDA
The PtDA was used by 69/123 of respondents (57 %) in
the intervention group (Table 2). Many of the non-users
(23/53 (43 %) of non-users, which is 19 % of all respon-
dents in the intervention group) mentioned that they had
not received a referral card or could not remember having
received one. Other reasons for not visiting the PtDA
website were not having an Internet connection, having
troubles finding the website, no interest and lack of time.
Of the PtDA website visitors, 65/69 (94 %) read the
general information and 61/69 (90 %) compared two or
more DMARDs. The exercises to gain insight into pref-
erences, doubts and questions were performed by 26/69
(38 %) of the users. Furthermore, 31/69 (47 %) of the
users saved or printed an information leaflet. The sum-
mary with user’s notes, preferences, doubts and ques-
tions was read by 50/69 (75 %), shown to others by 24/
69 (38 %), saved or printed by 34/69 (52 %) and taken to
their next appointment with the rheumatologist by 18/
69 (28 %) of the users.
Determinants of use of the PtDA by patients
When exploring determinants of use of the PtDA, a few
significant differences were found between users and non-
users (Table 3). Users were significantly younger and higher
educated. There were no associations between PtDA use
and gender, marital status and employment. Nor was use
associated with any of the health-related or preference-
related factors. The number of options suggested by the
rheumatologist was significantly associated with use of the
PtDA; patients who were offered more than one treatment
option, were more likely to use the PtDA than those who
were offered only one.
Appraisal of the PtDA
Overall, users were very positive about the PtDA website
(Table 4). Many respondents indicated that they learned
a lot from it. They also indicated that it contained new
information, helped them to gain insight into prefer-
ences, worries and questions, helped them to discuss
things with their rheumatologist and helped with making
a decision about the medication. They perceived it to be
very useful, easy to use, easy to understand and attract-
ive. The general information, the specific pharmaceutical
information and the comparison of DMARDs were per-
ceived as most useful. Furthermore, most participants
intended to use the PtDA again in the future and would
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recommend the PtDA to others. The overall quality of
the PtDA website received a grade 7.7 on a scale from 0
to 10.
Impact of the PtDA
Relative to the comparison group, patients in the inter-
vention group perceived significantly less often that the
doctor decided about initiating DMARDs, and more
often that they made the final decision about initiating
DMARDs (Table 5). With regard to the secondary out-
come measures, we found that patients in the interven-
tion group regarded the decision to be significantly
more consistent with their personal preferences than pa-
tients in the comparison group. Finally, more partici-
pants in the intervention group were offered more than
one medication option compared to patients in the com-
parison group, 46 % vs 12 %; p < 0.05, respectively. For
all other variables no significant differences were found
between the groups.
Discussion
This study was conducted to evaluate the use, appraisal
and impact of a PtDA for initiating DMARDs in patients
with rheumatic diseases. The PtDA is designed to im-
prove patient participation by supporting patients in de-
termining treatment preferences, worries and questions
and by endorsing them to express these feelings and
questions to their health professionals. The study dem-
onstrated that patients perceived the PtDA as very help-
ful in the decision-making process. Our primary
research question focused on the impact of the PtDA on
perceived role in medical decision-making. Relative to
the comparison group, patients in the intervention
group perceived a more active role in medical decision-
Table 1 Patient-related characteristics (n = 281)






Age, years 54 ± 15 (158) 55 ± 13 (123) n.s.b
Gender, % (n) Women 65 % (102) 61 % (75)
Men 35 % (56) 39 % (48) n.s.
Marital status, % (n) Married/living with partner 78 % (121) 89 % (109)
Not married/living alone 22 % (34) 11 % (14) 0.02
Education, % (n) Low 26 % (41) 30 % (37)
Medium 52 % (81) 50 % (61)
High 22 % (34) 20 % (25) n.s.
Work status, % (n) Employed/studying 67 % (82) 67 % (58)
Not employed/not studying 33 % (41) 33 % (29) n.s.
Health-related variables
Diagnosis, % (n) Rheumatoid arthritis 76 % (108) 81 % (91)
Psoriatic arthritis 19 % (27) 13 % (15)
Ankylosing spondylitis 5 % (7) 6 % (7) n.s.
Years since diagnosis, % (n) <1 37 % (58) 25 % (31)
1–5 34 % (52) 41 % (50)
6–10 10 % (16) 12 % (14)
>10 19 % (29) 22 % (27) n.s.
Pain (NRS) Range 0–10 4.7 ± 2,4 (158) 4.7 ± 2,5 (123) n.s.b
Physical function (HAQ-II) range 0–3 2.17 ± 0.57 (155) 2.13 ± 0.57 (120) n.s.b
Preference-related variables
Preferred role in decision-making (CPS), % (n) (Mostly) doctor 15 % (23) 8 % (10)
Shared 76 % (119) 77 % (94)
(Mostly) patient 9 % (14) 15 % (18) n.s.
Need for information (CPQ) range 1–5 4.4 ± 0.8 (154) 4.5 ± 0.7 (121) n.s.b
Values are the mean ± standard deviation (number) unless otherwise indicated. Percentages do not include missing cases. aTested using the Pearson chi-square
test unless otherwise indicated. bTested using the t test. n.s. not significant (p > 0.05), NRS numerical rating scale, HAQ-II Health Assessment Questionnaire, version
2 [28], CPS Control Preference Scale [5, 29], CPQ Cologne Preference Questionnaire [30, 31]
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making. Furthermore, decisions were more in line with
patients’ personal preferences. We found no differences
between groups in satisfaction with the decision-making
process, beliefs about medication, adherence or trust in
the physician. However, this may be due to ceiling ef-
fects or limited psychometric quality of some of the in-
struments used [40]. Generally, our results are in line
with the impact of other PtDAs, as was shown in a re-
cent systematic review [15].
By developing the PtDA in co-creation with patients
and health professionals we aimed to develop a user-
friendly PtDA that closely fits the needs of all users and
consequently eased adoption and implementation. This
study demonstrated that patients appreciated the PtDA
highly and perceived it as useful, usable and helpful in
the decision-making process.
The PtDA was used by 57 % of the patients in the
intervention group who had returned the questionnaire.
Users were mostly younger and higher educated pa-
tients. Compared to other studies on PtDAs in routine
practice and in clinical trials, our patient user rates are
high. In other routine practice studies, patients’ use of
PtDAs varied between 25 % and 37 % [41–43]. Clinical
trials report much higher patient user rates, varying
from 49 % to 85 % [44–46].
A recent systematic review suggests that adoption and
implementation of PtDAs using a referral model (i.e.
health professionals inviting eligible patients to use the
PtDA) is often challenged by indifference on the part of
health professionals [14]. This indifference may stem
from a lack of confidence in the content of PtDAs and
concerns about disruption of established workflow [14].
However, we believe that the relatively high percentage
of patients who used the PtDA in our study may partly
be explained by the active referral by the rheumatolo-
gists. Although we did not specifically assess factors en-
hancing system adoption in this study, we believe that
the high referral and usage rates could be attributed to
the iterative and extensive involvement of patients and
health professionals during the development process
[47]. To determine how to further increase the referral
rates to the PtDA, we recently conducted a focus group
study with health professionals, the results of which are
currently being analysed. Likewise, to further increase
patients’ PtDA use it should be investigated how the tool
can be further adapted to the needs of older and lower
educated patients.
Notably, we observed a significant difference between
the comparison group and the intervention group in the
number of treatment options offered by the rheumatolo-
gist. This might have biased the findings because when
patients are offered more than one option, or when
options are more explicitly discussed, patients might
(automatically) feel that their role in medical decision-
making is larger. However, the question remains why the
amount of options offered and registered by the rheuma-
tologists was higher in the second period of the study
(intervention group). There have been no apparent
changes in the availability of DMARDs, and the way
rheumatologists were asked to register the options of-
fered was identical in both periods. Interviewing some of
the participating rheumatologists revealed that the refer-
ral card and PtDA may have prompted the rheumatolo-
gists to more explicitly discuss options with patients and
consequently more accurately register the options of-
fered for the study.
Unfortunately, we cannot compare the effect on num-
ber of options offered to results for other PtDAs, be-
cause this is not a common measure in PtDA
evaluations. Previously studied PtDAs have largely fo-
cused on decisions on whether or not to initiate a treat-
ment or on choosing between a predefined limited
Table 2 Use of the patient decision aid (n = 123)
Tasks Percentage (n)
Visited the PtDA website 57 % (69)
Reasons for not visiting the PtDA websitea
Did not receive referral to the PtDA website or cannot
remember
19 % (23)
No Internet 7 % (8)
Could not find PtDA website 6 % (7)
Website did not work 1 % (1)
Not interested 6 % (7)
No time 6 % (7)
Missing (1)
Received explanation about PtDA
Yes 69 % (85)
No 22 % (27)
Cannot remember 9 % (11)
Tasks performed on the PtDA website (visitors only; n = 69)b
Read general information 94 % (65)
Compared two or more DMARDs 90 % (61)
Made notes in the digital notebook 16 % (11)
Performed exercises about preferences, worries and
questions
38 % (26)
Saved or printed an information leaflet 47 % (31)
Read the summary 75 % (50)
Showed the summary to others 38 % (24)
Saved or printed the summary 52 % (34)
Took the summary to their next appointment with
the rheumatologist
28 % (18)
Percentages do not include missing cases. aFor reasons for not visiting the
website, percentages are taken from the total population in the intervention
group (n = 123). bFor tasks performed, percentages are taken from visitors only
(n = 69). PtDA patient decision aid, DMARD disease modifying anti-rheumatic drug
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number of treatment options. Widely studied examples
include decisions like “Should I have chemotherapy for
early-stage breast cancer?” and “Should I have breast-
conserving surgery or a mastectomy for early-stage
breast cancer?” In rheumatology, previous PtDAs focused
on the decision on whether or not to initiate one specific
DMARD or a particular class of DMARDs [18, 19]. Com-
pared to these previously studied PtDAs, our PtDA en-
compasses many different treatment options. To reduce
the potentially overwhelming number of choices and to
eliminate all inappropriate options, we chose to let the
rheumatologist preselect which DMARDs are appropriate
choices for the individual patient at that specific moment.
To our knowledge, this innovative flexible referral model
has not previously been studied.
The main strength of this study is its virtual imple-
mentation of a PtDA in daily clinical practice. However,
due to limitations inherent in the study design, some
caution is needed when interpreting our results. First,
the post-test only study with a non-equivalent historical
comparison group is susceptible to the internal validity
of selection; any prior differences between the groups
may have affected the outcome of the study. Yet, despite
this limitation we chose this study design deliberately in
order to reduce contamination effects. If patients had
been randomized to a condition, namely PtDA or
Table 3 Determinants of use of the patient decision aid (n = 123)






Age, years 52 ± 13 (69) 58 ± 12 (53) 0.003b
Gender, % (n) Women 57 % (39) 68 % (36)
Men 43 % (30) 32 % (17) n.s.
Marital status, % (n) Married/living with partner 87 % (60) 91 % (48)
Not married/living alone 13 % (9) 9 % (5) n.s.
Education, % (n) Low 20 % (14) 43 % (23)
Medium 51 % (35) 47 % (25)
High 29 % (20) 9 % (5) 0.004
Employment, % (n) Employed/studying 65 % (33) 69 % (24)
Not employed/studying 35 % (18) 31 % (11) n.s.
Health-related variables
Diagnosis, % (n) Rheumatoid Arthritis 81 % (52) 80 % (39)
Psoriatic Arthritis 13 % (8) 14 % (7)
Ankylosing Spondylitis 6 % (4) 6 % (3) n.s.
Years since diagnosis, % (n) <1 19 % (13) 32 % (17)
1–5 43 % (29) 40 % (21)
6–10 13 % (9) 9 % (5)
>10 25 % (17) 19 % (10) n.s.
Pain (NRS) Range 0–10 4.7 ± 2.5 (69) 4.8 ± 2.8 (53) n.s.b
Physical function (HAQ-II) range 0–3 2.14 ± 0.70 (69) 2.10 ± 0.71 (53) n.s.b
Preference-related variables
Preferred role in decision-making (CPS), % (n) (Mostly) doctor 9 % (6) 8 % (4)
Shared 78 % (54) 75 % (39)
(Mostly) patient 13 % (9) 17 % (9) n.s.
Need for information (CPQ) range 1–5 4.6 ± 0.6 (69) 4.5 ± 0.7 (121) n.s.b
Number of treatment options
Suggested by rheumatologist, % (n) 1 option 38 % (23) 73 % (36)
>1 option 62 % (38) 27 % (13) 0.000
Values are the mean ± standard deviation (number) unless otherwise indicated. Percentages do not include missing cases. aTested using the Pearson chi-square
tests unless otherwise indicated. bTested using the t test. PtDA patient decision aid, n.s. not significant (p > 0.05), NRS numerical rating scale, HAQ-II Health Assessment
Questionnaire, version 2 [28], CPS Control Preference Scale [5, 29], CPQ Cologne Preference Questionnaire [30, 31]]
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standard information, physicians would have been ex-
posed to both conditions simultaneously, which might
have influenced their behaviour. Second, although we in-
cluded many variables in our study, it remains difficult
to control for all confounding variables. We realize that
in this study we did not evaluate merely the effect of the
PtDA. Introducing the PtDA obviously affected the
healthcare system and the daily workflow of health pro-
fessionals. Therefore, some caution is needed with causal
interpretations of our results. Finally, due to non-
response, our results might have been biased. It is likely
that the patients who do not need to participate in med-
ical decision-making or in using a PtDA are less inter-
ested in responding to a questionnaire about this
subject.
Future multi-centre randomized trials need to be
conducted to further study the impact of this PtDA and
to compare the impact of this PtDA with other SDM in-
terventions. A longitudinal study is needed to reveal
what the impact is on the number of sessions and on
cost-effectiveness. Furthermore, more research is needed
to determine how to involve lower educated patients








Subjective impact of the PtDA
I learned a lot from the PtDA 11 % 17 % 71 %
The PtDA contained new information 7 % 23 % 70 %
The PtDA helped me to gain insight into my preferences, worries and questions 9 % 22 % 70 %
The PtDA helped me in making a decision about medication 11 % 18 % 70 %
The PtDA helped me in discussing my preferences, worries and questions with
my rheumatologist
11 % 28 % 60 %
Total impact 3.8 ± 0.9
Perceived usefulness
The PtDA in general was useful 7 % 5 % 88 %
Reading the general information was useful 2 % 5 % 94 %
The specific information about DMARDs was useful 4 % 3 % 94 %
Comparing DMARDs was useful 4 % 8 % 89 %
Making notes in the digital notebook was useful 22 % 51 % 28 %
The exercises about preferences and worries were useful 11 % 29 % 59 %
The list of frequently asked questions was useful 12 % 32 % 56 %
Total usefulness 4.0 ± 0.7
Perceived ease of use
The website is easy to use 5 % 3 % 92 %
The information is easy to understand 2 % 6 % 92 %
The time the PtDA takes to finish is acceptable 5 % 5 % 90 %
The structure of the website is logical 10 % 11 % 79 %
Total ease of use 4.5 ± 0.8
Attractiveness
The colour of the website is pleasant 2 % 17 % 81 %
The font on the website is pleasant 4 % 9 % 87 %
Total attractiveness 4.4 ± 0.9
Attitude towards future use
I would use the PtDA again in the future 5 % 3 % 91 %
I would recommend the PtDA to others 2 % 7 % 89 %
Total attitude 4.6 ± 0.9
Overall grade regarding the quality of the PtDA (range 0–10) 7.7 ± 0.9
Percentages do not include missing cases. PtDA patient decision aid, DMARD disease modifying anti-rheumatic drug
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and patients in different age groups in medical decision-
making.
Conclusion
This study was conducted to evaluate use, appraisal and
impact of a PtDA for making decisions about initiating
DMARDs. The PtDA was used by the majority of the re-
spondents, was highly appreciated and was perceived as
helpful in the decision-making process. Relative to the
comparison group, patients perceived a more active role
in medical decision-making and felt the final choice to
be more consistent with their personal preferences.
From this study we can conclude that this PtDA can be
a valuable aid in improving patient participation in med-
ical decision-making about DMARDs.
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Perceived role in decision-making (CPS), % (n)
(Mostly) doctor 25 % (39) 14 % (17)
Shared 70 % (111) 73 % (90)
(Mostly) patient 5 % (8) 13 % (16) 0.01b
Satisfaction with decision and decision-making process
Satisfaction with participation (range 1–5) 4.6 ± 0.6 (144) 4.6 ± 0.6 (115) n.s.
Satisfaction with received information (range 0–21) 15.7 ± 4.9 (130) 15.3 ± 5.7 (106) n.s.
Informed choice (DES) (range 1–5) 4.2 ± 1.0 (145) 4.3 ± 0.9 (115) n.s.
Decision-control (DES) (range 1–5) 4.6 ± 0.5 (146) 4.6 ± 0.7 (114) n.s.
Satisfaction-uncertainty (DES) (range 1–5)c 4.0 ± 0.8 (147) 4.1 ± 0.7 (116) n.s.
Consistency with personal values (SWD) 4.2 ± 1.0 (148) 4.5 ± 0.8 (112) 0.02
Other categories
Beliefs about medication - necessity (range 5–25) 18.6 ± 4.5 (137) 19.6 ± 4.6 (87) n.s.
Beliefs about medication - concerns (range 5 − 25) 13.8 ± 4.1 (136) 12.9 ± 4.9 (90) n.s.
Medication adherence (MMAS) (range 0 − 8)d 7.2 ± 1.4 (129) 7.2 ± 1.4 (102) n.s.
Trust in physician (CPQ) (range 1 − 5) 4.8 ± 0.5 (155) 4.8 ± 0.4 (120) n.s.
Number of treatment options suggested by rheumatologist, % (n)
1 option 88 % (137) 54 % (60)
> 1 option 12 % (18) 46 % (51) 0.000
*Values are the mean ± standard deviation (number) unless otherwise indicated. aTested using the t test unless otherwise indicated. bTested using the Pearson
chi-square test. cHigher scores indicate less uncertainty and higher satisfaction. dAdherence not assessed in patients that get professional assistance with administrating
injections or go to the hospital for intravenous medication
n.s. not significant (p > 0.05), CPS Control Preference Scale [5, 29], DES Decision Evaluation Scales [35], SWD Satisfaction With Decision scale [36], BMQ Beliefs about
Medication Questionnaire [37], MMAS Morisky Medication Adherence Scale [38], CPQ Cologne Preference Questionnaire [30, 31]
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